Format

Send to

Choose Destination
Psychopharmacology (Berl). 2016 Sep;233(17):3113-24. doi: 10.1007/s00213-016-4346-2. Epub 2016 Jun 24.

Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats.

Author information

1
Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA. gsnyder@intracellulartherapies.com.
2
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, P.O. Box 616, NL-6200, Maastricht, MD, The Netherlands.
3
School of Natural Sciences, Linnaeus University, Kalmar, Sweden.
4
Intra-Cellular Therapies Inc., 430 East 29th Street, Suite 900, New York, NY, 10016, USA.
5
Tianjin Hospital, Tianjin, 300211, People's Republic of China.

Abstract

RATIONALE:

Therapeutic agents for memory enhancement in psychiatric disorders, such as schizophrenia, are urgently needed.

OBJECTIVE:

The aim of this study is to characterize the preclinical profile of ITI-214, a potent inhibitor of phosphodiesterase 1 (PDE1).

METHODS:

ITI-214 was assayed for inhibition of PDE1 versus other PDE enzyme families using recombinant human PDE enzymes and for off-target binding to 70 substrates (General SEP II diversity panel; Caliper Life Sciences). Effects of ITI-214 (0.1-10 mg/kg, po) on memory performance were assayed in rats using the novel object recognition (NOR) paradigm, with drug given at specified time points prior to or following exposure to objects in an open field. ITI-214 was evaluated for potential drug-drug interaction with risperidone in rats using conditioned avoidance response (CAR) and pharmacokinetic assessments.

RESULTS:

ITI-214 inhibited PDE1A (K i = 33 pmol) with >1000-fold selectivity for the nearest other PDE family (PDE4D) and displayed minimal off-target binding interactions in a 70-substrate selectivity profile. By using specific timing of oral ITI-214 administration, it was demonstrated in the NOR that ITI-214 is able to enhance acquisition, consolidation, and retrieval memory processes. All memory effects were in the absence of effects on exploratory behavior. ITI-214 did not disrupt the risperidone pharmacokinetic profile or effects in CAR.

CONCLUSIONS:

ITI-214 improved the memory processes of acquisition, consolidation, and retrieval across a broad dose range (0.1-10 mg/kg, po) without disrupting the antipsychotic-like activity of a clinical antipsychotic medication, specifically risperidone. Clinical development of ITI-214 is currently in progress.

KEYWORDS:

Conditioned avoidance response; Cyclic AMP; Cyclic GMP; Memory; Novel object recognition; Phosphodiesterase-1

PMID:
27342643
PMCID:
PMC4980415
DOI:
10.1007/s00213-016-4346-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center